Pioneering targeted radioligand therapies that deliver lethal radiation directly to cancer cells — sparing healthy tissue, transforming outcomes.
AIGA Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation radioligand therapies (RLTs). Our proprietary alpha-particle theranostic platform combines precision targeting with unparalleled cytotoxic power.
We are committed to patients whose cancers have progressed beyond available therapies — delivering hope through science.
Learn About Our ApproachOffer hope and transform the lives of people living with incurable cancers worldwide.
Pioneer next-generation targeted radiotherapeutics through our alpha-particle theranostic platform.
Achieve longer, healthier lives for cancer patients through relentless innovation and compassionate care.
Alpha particles are uniquely lethal to cancer cells while confining their destructive energy to a microscopic radius — making them ideal for precision oncology.
Alpha particles deliver a linear energy transfer (LET) 100× greater than beta particles, inducing irreparable double-strand DNA breaks within a 3–10 cell diameter radius.
Our theranostic approach unifies diagnostic imaging and targeted therapy in a single molecular framework — enabling patient selection, treatment monitoring, and dose optimization simultaneously.
Our ligands are engineered to bind with high affinity to tumor-specific molecular markers, delivering the radioactive payload precisely where it is needed while sparing surrounding healthy tissue.
Diagnostic companion imaging pinpoints tumor-specific receptor expression across the patient's disease burden.
The radioligand seeks out and binds to overexpressed receptors on cancer cells with high selectivity.
Alpha-particle decay unleashes lethal double-strand DNA breaks confined to within a few cell diameters.
Post-treatment imaging confirms tumor response and guides adaptive therapy decisions in real time.
Our portfolio addresses cancers where current treatments fall short, leveraging our alpha-particle platform across multiple oncology indications.
| Program | Target | Indication | Approach | Development Stage | |||
|---|---|---|---|---|---|---|---|
| Preclinical | Phase I | Phase II | Phase III | ||||
| AIGA-001 | Undisclosed | Aerodigestive Tumors | Alpha RLT | ||||
| AIGA-002 | Undisclosed | Central Nervous System Tumors | Alpha RLT | ||||
| AIGA-003 | Undisclosed | Gastrointestinal Tumors | Alpha RLT | ||||
Pipeline programs are in various stages of preclinical and clinical development. Program names and indications are for illustrative purposes pending public disclosure.
Alpha particles deposit energy ~100× more densely than beta particles, causing irreparable DNA damage in a single pass.
The 3–10 cell radius of effect minimizes off-target damage, preserving bone marrow and surrounding healthy structures.
The high cytotoxic potency of alpha particles enables effective tumour control with fewer treatment cycles compared to conventional radiotherapy.
Companion diagnostics enable patient stratification and real-time treatment monitoring using the same molecular vector.
A guided-missile approach to cancer — engineering molecules that seek, bind, and destroy tumour cells with atomic precision while leaving healthy tissue intact.
A tumour-targeting ligand is conjugated to an alpha-emitting radioisotope (Ac-225), forming the precision radioligand.
Administered intravenously, the radioligand circulates through the bloodstream, reaching every corner of the body.
The ligand recognises and locks onto tumour-specific receptors overexpressed on cancer cells with nanomolar affinity.
Alpha particles unleash lethal DNA double-strand breaks within a 40–90 µm radius — obliterating the tumour cell while sparing neighbours.
Because alpha particles travel only 2–3 cell diameters, normal tissue surrounding the tumour receives negligible radiation dose — a key advantage over conventional radiotherapy and beta-emitting RLTs.
We welcome inquiries from investors, research collaborators, clinical partners, and members of the media. Our team is ready to explore how AIGA Therapeutics can advance your goals.
info@aigatherapeutics.comWe typically respond within 2 business days.